We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Read MoreHide Full Article
In the latest market close, Humacyte, Inc. (HUMA - Free Report) reached $8.29, with a -0.72% movement compared to the previous day. The stock's performance was behind the S&P 500's daily loss of 0.16%. At the same time, the Dow lost 0.14%, and the tech-heavy Nasdaq lost 0.06%.
Heading into today, shares of the company had gained 63.73% over the past month, outpacing the Medical sector's gain of 0.37% and the S&P 500's gain of 1.96% in that time.
Market participants will be closely following the financial results of Humacyte, Inc. in its upcoming release. The company's earnings per share (EPS) are projected to be -$0.23, reflecting a 4.55% decrease from the same quarter last year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Humacyte, Inc. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Humacyte, Inc. is currently a Zacks Rank #5 (Strong Sell).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 82, finds itself in the top 33% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the latest market close, Humacyte, Inc. (HUMA - Free Report) reached $8.29, with a -0.72% movement compared to the previous day. The stock's performance was behind the S&P 500's daily loss of 0.16%. At the same time, the Dow lost 0.14%, and the tech-heavy Nasdaq lost 0.06%.
Heading into today, shares of the company had gained 63.73% over the past month, outpacing the Medical sector's gain of 0.37% and the S&P 500's gain of 1.96% in that time.
Market participants will be closely following the financial results of Humacyte, Inc. in its upcoming release. The company's earnings per share (EPS) are projected to be -$0.23, reflecting a 4.55% decrease from the same quarter last year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Humacyte, Inc. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Humacyte, Inc. is currently a Zacks Rank #5 (Strong Sell).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 82, finds itself in the top 33% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.